
|Articles|November 9, 2012
- November 2012 Cough & Cold
- Volume 78
- Issue 11
Second Annual Essay Contest Deadline Approaching
Advertisement
The deadline for our second annual essay contest is fast approaching! In 500 words or less, describe your best day as a pharmacist—and become eligible to win a $100 gift card.
Entries can be e-mailed to
Articles in this issue
about 14 years ago
Can You Read These Rxs?about 14 years ago
Drug Diversion and Abuse: Finding Balance in the Rx Worldabout 14 years ago
Generic Patent Settlement Cases Could Head to Supreme Courtabout 14 years ago
Generic Drugs Cut Costs for Independent Pharmaciesabout 14 years ago
FDA Expert: Generics Safe, Effectiveabout 14 years ago
Generic Product Newsabout 14 years ago
Health App WrapAdvertisement
Related to this article

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

Preserving patient access requires attention to the people, workflows, and financial structures behind the pharmacy counter, not just the number of open pharmacy locations.

The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.

Peer Reviewed
Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
2
Giredestrant Plus Everolimus Wins FDA Approval in ESR1-Mutated Advanced Breast Cancer
3
Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C
4
US Loses Measles Elimination Status After 26 Years
5


